Vol 2, No 12 (2022)

Reimbursement Recommendations

Pitolisant Hydrochloride (Wakix)

CADTH

Published December 22, 2022

PDF HTML

Pembrolizumab (Keytruda)

CADTH

Published December 19, 2022

PDF HTML

Ozanimod (Zeposia)

CADTH

Published December 5, 2022

PDF HTML

Guselkumab (Tremfya)

CADTH

Published December 5, 2022

PDF HTML

Tezepelumab (Tezspire)

CADTH

Published December 2, 2022

PDF HTML

Mepolizumab (Nucala)

CADTH

Published December 2, 2022

PDF HTML

Dalbavancin (Xydalba)

CADTH

Published December 2, 2022

PDF HTML

Reimbursement Reviews

Nivolumab (Opdivo)

CADTH

Published December 23, 2022

PDF HTML

Abemaciclib (Verzenio)

CADTH

Published December 23, 2022

PDF HTML

Selpercatinib (Retevmo)

CADTH

Published December 22, 2022

PDF HTML

Pembrolizumab (Keytruda)

CADTH

Published December 15, 2022

PDF HTML

Atezolizumab (Tecentriq)

CADTH

Published December 15, 2022

PDF HTML

Semaglutide (Wegovy)

CADTH

Published December 9, 2022

PDF HTML

Tepotinib (Tepmetko)

CADTH

Published December 8, 2022

PDF HTML

Atezolizumab (Tecentriq)

CADTH

Published December 8, 2022

PDF HTML

Pembrolizumab in Combination With Lenvatinib (Keytruda and Lenvima)

CADTH

Published December 6, 2022

PDF HTML

Health Technology Reviews

Post‒COVID-19 Condition Treatment and Management Rapid Scoping Review

Yi-Sheng Chao, Sarah C. McGill, Michelle Gates, Thyna Vu, Angie Hamson

Published December 22, 2022

PDF HTML

Virtual Care Rapid Scoping: Main Report

CADTH

Published December 7, 2022

PDF HTML

Bevacizumab for the Treatment of Patients With Brain Radionecrosis

Shannon Hill, Danielle MacDougall

Published December 5, 2022

PDF HTML

Subtypes of Post–COVID-19 Condition: A Review of the Emerging Evidence

Sinwan Basharat, Yi-Sheng Chao, Sarah C. McGill

Published December 5, 2022

PDF HTML

View All Issues